A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine

CHA Vaccine Institute

Status and phase: Completed; Phase 2

Conditions: Hepatitis B, Chronic

Treatments: Biological: Normal Saline(placebo); Biological: CVI-HBV-002

Study type: Interventional

Funder types: Industry

Identifiers

NCT04289987

CVI-HBV-002-CT1901

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of the investigational medicinal product CVI-HBV-002.

Full description

A randomized, double-blinded, placebo-controlled, parallel, multicenter, phase 2b study to evaluate the efficacy and safety of CVI-HBV-002 in patients with chronic hepatitis B taking Tenofovir disoproxil fumarate/Tenofovir disoproxil

Enrollment: 134 patients

Sex: All

Ages: 19 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adult between 19 to 60 years of age
2. Those who have been diagnosed as chronic hepatitis B patients (e.g.HBsAg positive detected for 6 months or more)
3. Started treatment with Tenofovir Disoproxil Fumarate(TDF) or Tenofovir Diproxil(TD), oral HBV antiviral agent, for 6 months to 5 years.
4. HBsAg ≥ 100 IU/mL, HBV DNA ≤ 100 IU/mL at screening
5. HBV DNA ≤ 2000 IU/mL at screening
6. ALT ≤ Upper Limit of Normal) x 2 at screening
7. Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures

Exclusion criteria

1. Patients with other hepatic disease other than chronic hepatitis B(e.g., hemochromatosis, Wilson disease, alcoholic liver disease, nonalcoholic steatohepatitis, alpha-1 antitrypsin deficiency, etc)

2. If any of the following laboratory tests were found at screening

   • Total bilirubin > Upper Limit of Normal x 2
   • Prothrombin time delayed more than 3 seconds than normal
   • Serum Albumin < 30 g/L (3 g/dL)
   • Hemoglobin < 9.0 g/dL eGFR < 60 mL/min (Cockcroft-Gault)
   • Absolute neutrophil count (ANC) < 1.5 x 10^9 /L (1500 /mm3)
   • Platelet count < 100 x 10^9 /L (100 x 10^3 /mm3)
   • Serum creatinine > 1.5 mg/dL
   • Serum amylase > 2 x ULN and Lipase > 2 x ULN

3. A history of ascites, jaundice, varicoses vein bleeding, hepatic encephalopathy, or other signs of liver failure

4. Treated with oral antiviral agents or interferon therapy other than TDF(or TD)

5. In case of receiving nephroxic drugs(Aminoglycosides, Amphotericin B, NSAIDs, etc.) within 14 days prior to screening

6. When hepatotoxic drugs(Erythromycin, Ketoconazole, Rifampin, Fluconazole, Dapsone, etc.) are administered within 14 days prior to screening

7. Patients with active bacterial, viral or fungal infections requiring systemic treatment

8. Patients diagnosed with Alpha-fetoprotein (AFP) >50 ng/mL or with Hepatocellular Carcinoma (HCC) in screening

9. Of those who have received immunosuppressive drugs within 6 months prior to screening, patients suspected of having decreased immunity by the judgment of the Investigator

10. Patients who have received high dose (prednisone 20mg or more*) systemic corticosteroids for a long period of time(consecutive 14 days or longer) within 3 months before screening (at the discretion of the investigator in case of local corticosteroids)

    * Corresponding to 125 mg of cortisone, 100 mg of hydrocortisone, 20 mg of prednisone, 16 mg of methylpreprednisolone, 16 mg of triamsynolone, 3 mg of dexamethasone and 2.4 mg of betametasone.

11. Patients who have been diagnosed with malignant tumors within 5 years before screening, or who have recurred malignant tumors(in case of benign tumors, if the Investigator considers that the progress of the clinical trial is not affected during the clinical trial)

12. Organ transplantation recipients

13. Patients with serious illnesses, such as heart failure, renal failure, and pancreatitis, other than liver disease

14. Patients with a history of serious heart disease (NYHA Functional Class III or IV heart failure, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring treatment or unstable angina)

15. Patients with seizure disorders who require anticonvulsant therapy

16. HbA1c>7.5%

17. SBP≥140mmHg or DBP≥90mmHg

18. Patients infected with hepatitis C(HCV), hepatitis D(HDV) or human immunodeficiency virus(HIV)

19. A hypersensitivity or anaphylactic reaction to the components of the clinical trial drug or HBV vaccine components

20. Continued drinking(>21 units/week, 1 unit = 10g of pure alcohol) or alcohol dependence

21. Pregnancy or breastfeeding, or cannot agree with the approved method of contraception of the patient and partner during the clinical trial(e.g., infertility surgery, intrauterine contraceptive, oral contraceptive and concomitant use of diaphragm or condom, other hormonal delivery systems and concomitant use of diaphragm or condom)

22. Patients who are concerned about the deterioration of daily function due to mental illness or who cannot understand the purpose and method of this trial

23. Patient who has potential to severe febrile or systemic reaction

24. Patients who are scheduled to participate in other clinical trials after enrolling in this trial, or have participated in other clinical trials within 3 month of enrollment in this trial

25. Others those who are considered to be difficult to perform the clinical trial by the judgment of the Investigator

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

134 participants in 2 patient groups, including a placebo group

CVI-HBV-002

Experimental group

Description:

* CVI-HBV-002 1.0mL(20ug/dose) * Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses

Treatment:

Biological: CVI-HBV-002

Normal Saline

Placebo Comparator group

Description:

* Normal Saline Choonwae Inj. 1.0 mL * Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses

Treatment:

Biological: Normal Saline(placebo)